Developer docs
API playgroundTry for free, no card

Search company profiles

Ironshore Pharmaceuticals

Full company profile

uuid00024bx

Namestring
Ironshore Pharmaceuticals
Legal namestring
Collegium Pharmaceutical, Inc.
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Ironshore Pharmaceuticals Inc. is a privately held specialty pharmaceutical company founded in 2008 and headquartered in Morrisville, North Carolina. The company's stated mission is to develop treatment options that improve the lives of patients, with a therapeutic focus evidenced by its ADHD product franchise, including JORNAY PM, a methylphenidate-based treatment distinguished by its evening-dosing profile. The firm employs between 101 and 250 people and operates a full commercial-stage organization led by a CEO (Stephanie Read), Chief Commercial Officer (Danny Villeneuve), Chief Scientific Officer (Bev Incledon), Chief Medical Officer (Lewis Warrington), Chief Information Officer (Tim Branz), and Chief People Officer (Micheal Westphall).

The company's core product technology centers on proprietary drug formulations targeting central nervous system / ADHD indications. Its flagship commercial product, JORNAY PM, was the first and only evening-dosed methylphenidate treatment available in Canada as of its October 2025 launch there via a partnership with Knight Therapeutics, signaling a partner-driven international commercialization model rather than standalone international infrastructure. In January 2017, the company raised $200,000,000 in a financing round led by Morgan Stanley, indicating substantial institutional backing consistent with a commercial-stage specialty pharma scaling its revenue base.

Ironshore's revenue model is not directly disclosed in the available source material, but is consistent with a specialty pharmaceutical commercial model: sales of FDA-approved prescription medications to patients via prescribers and pharmacy benefit managers, supplemented by international out-licensing/distribution partnerships (such as Knight Therapeutics for Canada) to extend geographic reach without building parallel commercial organizations. Customer concentration risk appears low at the end-patient level but moderate at the international-distribution-partner level for Canada. No specific AI/ML capabilities are evident in the disclosed information, with competitive differentiation resting on drug formulation know-how, regulatory approvals, and commercial execution in ADHD therapeutics.

Short descriptiontext

Ironshore Pharmaceuticals is a private specialty pharmaceutical company headquartered in Morrisville, NC, developing and commercializing differentiated ADHD treatments such as JORNAY PM, an evening-dosed methylphenidate therapy, for patients and healthcare providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ADHD medications, central nervous system pharmaceuticals, methylphenidate treatments, extended-release formulations, neurology drug development
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
ADHD Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ironshore Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for serious neurological conditions, with a portfolio centered on ADHD (attention deficit hyperactivity disorder). Its differentiated products include evening-dosed methylphenidate formulations designed to address unmet needs in ADHD symptom management across the day.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Collegium Pharmaceutical is a diversified biopharmaceutical company with a portfolio of differentiated medications to treat serious medical conditions. The company is building a leading position in the ADHD treatment space, having acquired AZSTARYS® from Corium Therapeutics in May 2026, complementing their existing product portfolio. Their approach emphasizes leading with science to support people living with serious medical conditions and the healthcare professionals caring for them.

Product and service2 records
1JORNAY PM
CategoryADHD Pharmaceuticals
Description

Evening-dosed methylphenidate treatment for ADHD, designed to provide symptom control from morning through the day. Targeted at patients with attention deficit hyperactivity disorder and prescribed by healthcare professionals.

2AZSTARYS
CategoryADHD Pharmaceuticals
Description

A differentiated medication for the treatment of ADHD, acquired by Collegium Pharmaceutical from Corium Therapeutics in May 2026 to complement the ADHD portfolio.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty CNS pharmaceutical company focused on ADHD treatments (e.g., Qelbree) and other CNS products. Directly comparable to Ironshore as a CNS/ADHD-focused branded specialty pharma with differentiated dosing technology.

TypeDirect peer
Description

CNS-focused specialty pharma that developed and commercialized AZSTARYS, which Collegium acquired from Corium in May 2026. Closely comparable as an ADHD specialty pharmaceutical developer with branded stimulant assets.

TypeDirect peer
Description

Private specialty pharma focused on ADHD and other CNS products, known for extended-release/liquid stimulant formulations. Comparable technology platform to Ironshore's extended-release methylphenidate work.

TypeBroad incumbent
Description

Large pharmaceutical company commercializing Vyvanse, a leading branded ADHD medication. Comparable as a major player in the same ADHD therapeutic category with overlapping patient population.

TypeBroad incumbent
Description

Johnson & Johnson subsidiary marketing Concerta (extended-release methylphenidate). Directly comparable as a major extended-release methylphenidate product in the same ADHD market.

6Rhodes Pharmaceuticals
TypeDirect peer
Description

Specialty/generic pharmaceutical company with ADHD stimulant product portfolio. Comparable as a competitor in the methylphenidate ADHD market with overlapping prescriber base.

TypeDirect peer
Description

Specialty pharmaceutical company with CNS/ADHD transdermal and oral products. Comparable as a CNS-focused specialty pharma with differentiated ADHD delivery technology.

TypeDirect peer
Description

Specialty pharmaceutical company developing extended-release ADHD medications (e.g., Adzenys XR-ODT). Directly comparable as a smaller ADHD-focused branded specialty pharma with extended-release technology.

TypeDirect peer
Description

Publicly traded specialty pharmaceutical company (NASDAQ: COLL) focused on CNS and pain products that has acquired Ironshore assets. Closely tied as the acquirer/integrator of the JORNAY PM franchise.

TypeBroad incumbent
Description

Large pharmaceutical company marketing Strattera for ADHD. Comparable as a major branded ADHD player with overlapping patient/prescriber base, though broader portfolio beyond ADHD.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ironshore Pharmaceuticals

ADHD Pharmaceuticalsironshorepharma.com

Ironshore Pharmaceuticals is a private specialty pharmaceutical company headquartered in Morrisville, NC, developing and commercializing differentiated ADHD treatments such as JORNAY PM, an evening-dosed methylphenidate therapy, for patients and healthcare providers.

What Ironshore Pharmaceuticals does

Ironshore Pharmaceuticals Inc. is a privately held specialty pharmaceutical company founded in 2008 and headquartered in Morrisville, North Carolina. The company's stated mission is to develop treatment options that improve the lives of patients, with a therapeutic focus evidenced by its ADHD product franchise, including JORNAY PM, a methylphenidate-based treatment distinguished by its evening-dosing profile. The firm employs between 101 and 250 people and operates a full commercial-stage organization led by a CEO (Stephanie Read), Chief Commercial Officer (Danny Villeneuve), Chief Scientific Officer (Bev Incledon), Chief Medical Officer (Lewis Warrington), Chief Information Officer (Tim Branz), and Chief People Officer (Micheal Westphall).

The company's core product technology centers on proprietary drug formulations targeting central nervous system / ADHD indications. Its flagship commercial product, JORNAY PM, was the first and only evening-dosed methylphenidate treatment available in Canada as of its October 2025 launch there via a partnership with Knight Therapeutics, signaling a partner-driven international commercialization model rather than standalone international infrastructure. In January 2017, the company raised $200,000,000 in a financing round led by Morgan Stanley, indicating substantial institutional backing consistent with a commercial-stage specialty pharma scaling its revenue base.

Ironshore's revenue model is not directly disclosed in the available source material, but is consistent with a specialty pharmaceutical commercial model: sales of FDA-approved prescription medications to patients via prescribers and pharmacy benefit managers, supplemented by international out-licensing/distribution partnerships (such as Knight Therapeutics for Canada) to extend geographic reach without building parallel commercial organizations. Customer concentration risk appears low at the end-patient level but moderate at the international-distribution-partner level for Canada. No specific AI/ML capabilities are evident in the disclosed information, with competitive differentiation resting on drug formulation know-how, regulatory approvals, and commercial execution in ADHD therapeutics.

Ironshore Pharmaceuticals firmographics

Firmographics
Name
Ironshore Pharmaceuticals
Legal name
Collegium Pharmaceutical, Inc.
Website
https://ironshorepharma.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Ironshore Pharmaceuticals is a private specialty pharmaceutical company headquartered in Morrisville, NC, developing and commercializing differentiated ADHD treatments such as JORNAY PM, an evening-dosed methylphenidate therapy, for patients and healthcare providers.
Ownership category
akta.pro rank

Ironshore Pharmaceuticals industry classification

Industry
Product category
ADHD Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • ADHD medications
  • Central nervous system pharmaceuticals
  • Methylphenidate treatments
  • Extended-release formulations
  • Neurology drug development

Where Ironshore Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Markets served

Ironshore Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Ironshore Pharmaceuticals product offering

Product offering

Core offering

Ironshore Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for serious neurological conditions, with a portfolio centered on ADHD (attention deficit hyperactivity disorder). Its differentiated products include evening-dosed methylphenidate formulations designed to address unmet needs in ADHD symptom management across the day.

Product overview

Collegium Pharmaceutical is a diversified biopharmaceutical company with a portfolio of differentiated medications to treat serious medical conditions. The company is building a leading position in the ADHD treatment space, having acquired AZSTARYS® from Corium Therapeutics in May 2026, complementing their existing product portfolio. Their approach emphasizes leading with science to support people living with serious medical conditions and the healthcare professionals caring for them.

Differentiator

Problem solved

Functional benefit

Products and services

  • JORNAY PM Evening-dosed methylphenidate treatment for ADHD, designed to provide symptom control from morning through the day. Targeted at patients with attention deficit hyperactivity disorder and prescribed by healthcare professionals.
  • AZSTARYS A differentiated medication for the treatment of ADHD, acquired by Collegium Pharmaceutical from Corium Therapeutics in May 2026 to complement the ADHD portfolio.

Companies that use Ironshore Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Ironshore Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Ironshore Pharmaceuticals partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Ironshore Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Supernus Pharmaceuticals: Specialty CNS pharmaceutical company focused on ADHD treatments (e.g., Qelbree) and other CNS products. Directly comparable to Ironshore as a CNS/ADHD-focused branded specialty pharma with differentiated dosing technology.
  • Corium Therapeutics: CNS-focused specialty pharma that developed and commercialized AZSTARYS, which Collegium acquired from Corium in May 2026. Closely comparable as an ADHD specialty pharmaceutical developer with branded stimulant assets.
  • Tris Pharma: Private specialty pharma focused on ADHD and other CNS products, known for extended-release/liquid stimulant formulations. Comparable technology platform to Ironshore's extended-release methylphenidate work.
  • Rhodes Pharmaceuticals: Specialty/generic pharmaceutical company with ADHD stimulant product portfolio. Comparable as a competitor in the methylphenidate ADHD market with overlapping prescriber base.
  • Noven Pharmaceuticals: Specialty pharmaceutical company with CNS/ADHD transdermal and oral products. Comparable as a CNS-focused specialty pharma with differentiated ADHD delivery technology.
  • Neos Therapeutics: Specialty pharmaceutical company developing extended-release ADHD medications (e.g., Adzenys XR-ODT). Directly comparable as a smaller ADHD-focused branded specialty pharma with extended-release technology.
  • Collegium Pharmaceutical: Publicly traded specialty pharmaceutical company (NASDAQ: COLL) focused on CNS and pain products that has acquired Ironshore assets. Closely tied as the acquirer/integrator of the JORNAY PM franchise.

Broad incumbents

  • Takeda Pharmaceutical (Vyvanse franchise): Large pharmaceutical company commercializing Vyvanse, a leading branded ADHD medication. Comparable as a major player in the same ADHD therapeutic category with overlapping patient population.
  • Janssen Pharmaceuticals (Concerta): Johnson & Johnson subsidiary marketing Concerta (extended-release methylphenidate). Directly comparable as a major extended-release methylphenidate product in the same ADHD market.
  • Eli Lilly (Strattera): Large pharmaceutical company marketing Strattera for ADHD. Comparable as a major branded ADHD player with overlapping patient/prescriber base, though broader portfolio beyond ADHD.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Ironshore Pharmaceuticals social profiles

Digital presence

Ironshore Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ironshore Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Ironshore Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ironshore Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ironshore Pharmaceuticals

What does Ironshore Pharmaceuticals do?

Ironshore Pharmaceuticals is a pharmaceutical company that develops and commercializes treatments for serious neurological conditions, with a portfolio centered on ADHD (attention deficit hyperactivity disorder). Its differentiated products include evening-dosed methylphenidate formulations designed to address unmet needs in ADHD symptom management across the day.

Is Ironshore Pharmaceuticals a public or private company?

Ironshore Pharmaceuticals is a public company. It is classified as corporate owned and is currently operating.

When was Ironshore Pharmaceuticals founded?

Ironshore Pharmaceuticals was founded in 2008. It employs 11 to 50 people.

Where is Ironshore Pharmaceuticals based?

Ironshore Pharmaceuticals is headquartered in Morrisville, United States, in the North America region.

Who are Ironshore Pharmaceuticals's main competitors?

Direct peers on record are Supernus Pharmaceuticals, Corium Therapeutics, Tris Pharma, Rhodes Pharmaceuticals, Noven Pharmaceuticals, Neos Therapeutics and Collegium Pharmaceutical. Broad incumbents are Takeda Pharmaceutical (Vyvanse franchise), Janssen Pharmaceuticals (Concerta) and Eli Lilly (Strattera).

Does Ironshore Pharmaceuticals have an API?

No public API is recorded for Ironshore Pharmaceuticals.

What industry is Ironshore Pharmaceuticals in?

Ironshore Pharmaceuticals's product category is ADHD Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaCollegium Pharmaceutical: Strong Growth With Pain Management And ADHD ExpansionCollegium Pharmaceutical reported Q3 2024 revenue growth of 17% year-over-year, with EBIT margins improving to 35.2%. Its pain management portfolio accounts for 92.8% of revenues, and the company acquired Ironshore Therapeutics to add Jornay PM for ADHD, targeting a $30.6 billion market by 2032. The company faces high financial debt and integration risks.Business & FinancialCollegium Completes Acquisition Of Ironshore TherapeuticsCollegium completed its acquisition of Ironshore Therapeutics, paying $525 million in cash for all outstanding shares. The deal adds Jornay PM, an ADHD stimulant, to its portfolio, with 2024 product revenue guidance raised to $620–$635 million. The acquisition is expected to immediately accrete to adjusted EBITDA and cash flow.Seeking AlphaCollegium Pharmaceutical: Making Steady Progress After Q2 Results (NASDAQ:COLL)Collegium Pharmaceuticals acquired Ironshore Therapeutics for $525 million, adding Jornay PM to its portfolio. The purchase is expected to replace Nucynta revenues as the latter's patent expires. The company reported better-than-expected Q2 results, and its stock trades under six times trailing earnings.GlobeNewswireCollegium to Acquire Ironshore Therapeutics, Expanding into NeurologyCollegium Pharmaceutical agreed to acquire Ironshore Therapeutics for $525 million in cash, plus a potential $25 million milestone. The deal adds Jornay PM, an ADHD stimulant, with H1'24 prescriptions up 32% year-over-year. The transaction is expected to close in Q3 2024.GlobeNewswireCollegium to Acquire Ironshore Therapeutics, Expanding into NeurologyCollegium Pharmaceutical agreed to acquire Ironshore Therapeutics for $525 million in cash, plus a potential $25 million milestone. The deal adds Jornay PM, an ADHD stimulant, with H1'24 prescriptions up 32% year-over-year. The transaction is expected to close in Q3 2024.CollegiumpharmaCollegium to Acquire Ironshore Therapeutics, Expanding into Neurology – Collegium Pharmaceutical Inc.Collegium Pharmaceutical has announced a definitive agreement to acquire Ironshore Therapeutics for $525 million in cash, aiming to expand its portfolio into the neurology market with the ADHD drug Jornay PM. The transaction is expected to close in the third quarter of 2024 and will be funded by Collegium's existing cash and new financing that reduces its cost of capital. This move diversifies Collegium beyond pain management into a growing specialty pharmaceutical segment where Jornay PM has shown significant prescription growth.YahooCollegium to Acquire Ironshore Therapeutics, Expanding into NeurologyCollegium Pharmaceutical, Inc. has announced an agreement to acquire Ironshore Therapeutics Inc. for $525 million in cash, with the potential for an additional $25 million commercial milestone payment. This acquisition aims to expand Collegium's presence into the neurology market, particularly in ADHD treatment, leveraging Ironshore's product Jornay PM, which has seen a 32% increase in prescriptions year-over-year. The deal is expected to be immediately accretive to Collegium’s adjusted EBITDA and supports the company's strategic objectives in diversifying its pharmaceutical portfolio.Stock TitanCollegium to Acquire Ironshore Therapeutics, Expanding into NeurologyCollegium Pharmaceutical has entered into a definitive agreement to acquire Ironshore Therapeutics for $525 million in cash, aiming to expand its portfolio into the neurology market through Ironshore's ADHD medication Jornay PM. The transaction is expected to close in the third quarter of 2024 and is funded by Collegium's existing cash and new financing from Pharmakon Advisors. This acquisition marks a strategic diversification for Collegium beyond its traditional pain management business.GlobeNewswireCollegium to Acquire Ironshore Therapeutics, Expanding into NeurologyCollegium Pharmaceutical announced a definitive agreement to acquire Ironshore Therapeutics for $525 million in cash to expand its portfolio into the neurology market. The transaction includes the acquisition of Jornay PM, an ADHD medication that saw 32% prescription growth in the first half of 2024, and is expected to be immediately accretive to adjusted EBITDA. Collegium will fund the deal using existing cash and a new five-year financing arrangement, with the acquisition anticipated to close in the third quarter of 2024.GlobeNewswireKnight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin AmericaKnight Therapeutics entered an exclusive supply and distribution agreement with Ironshore Pharmaceuticals to commercialize JORNAY PM in Canada and Latin America. The drug, an extended-release methylphenidate for ADHD, was submitted for Canadian approval in November 2023. Financial terms were not disclosed.